查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1279656

2022-2029年全球微生物組治療劑市場規模研究與預測，按類型（FMT、微生物組藥物）、按應用（艱難梭菌、克羅恩病、炎症性腸病、糖尿病、其他）和區域分析。

Global Microbiome Therapeutics Market Size study & Forecast, by Type (FMT, Microbiome Drugs), By Application (C. difficile, Crohn's Disease, Inflammatory Bowel Disease, Diabetes, Others) and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格

2021年，全球微生物組治療市場的價值約為921.5億美元，預計在2022-2029年的預測期內將以超過35.32%的健康增長率增長。微生物組治療旨在通過應用本地或合成細菌、抗生素、噬菌體和細菌素進行加法、減法或調節性治療，對腸道微生物組進行改造。由於微生物組療法領域的研發，產品開發和產品群組擴展的戰略合作夥伴關係的增加等因素，市場正在擴大。大多數正在開發的治療藥物仍處於早期階段，通常在I期和II期之間。在這23種藥物中，超過13種藥物正在研究胃腸道適應症，其中大多數集中在潰瘍性結腸炎上。例如，Seres Therapeutics， Inc. 在 109 年披露了其 3 期 ECOSPOR III 研究的 SER-2021 試驗結果。計劃在2023年上半年推出管線藥物，作為復發性艱難梭菌感染的口服治療。與安慰劑相比，SER-109與抗菌素耐藥性基因的減少有關。此外，哈德遜研究所和BiomeBank之間建立了為期4年的微生物藥物開發和發現的伙伴關係。

隨著目標疾病越來越普遍，對微生物組療法的需求也在上升。微生物組研究的發展有望尋找更有效的感染和其他疾病治療方法，改善藥物治療的結果。公司正在降低其商品成本，增加更多人口獲得尖端醫療保健的機會，一些國家的管理當局正在改變其戰略，以支持採用基於微生物組的治療方法。因此，這為市場供應商提供了有利可圖的增長機會，以增加其市場份額。微生物組治療的高成本和產品複雜性帶來的嚴格監管規則是限制市場擴張的兩個主要問題。

全球微生物組治療法市場研究涵蓋的主要地區包括亞太、北美、歐洲、拉丁美洲和世界其他地區。 2021年，北美擁有最大的市場佔有率，主導了該行業。該地區的主導地位主要是由於其完善的研究能力，以創造創新的治療方法，以及其不斷擴大的目標人群。另外，像加拿大微生物組計劃（CMI）這樣的計劃在加拿大無處不在，使其更容易與合作夥伴和利益相關者合作。這使得集中研究力量創建微生物藥物成為可能。例如，Biocodex微生物群基金會在2021年7月發布了一項呼籲，要求在加拿大提交總額超過26,000美元的微生物群研究資金。這些激勵措施預計將刺激新的市場創新。據預測，在預測期內，亞太地區將大幅增長，原因是老年病和目標人群不斷增加，生物仿製藥開發的合作數量增加，主要參與者的地理擴張，以及政府和非營利組織在市場空間的積極參與等因素。

該研究的目的是定義近年來不同市場區隔和國家的市場規模，並預測未來幾年的價值。該報告旨在涵蓋參與研究的國家/地區的該行業的定性和定量方面。

該報告還提供了關於關鍵方面的詳細資訊，如驅動因素和挑戰，這將確定市場的未來增長。此外，它還涵蓋了微觀市場的潛在機會，供利益相關者投資，並詳細分析了競爭格局和主要參與者的產品。 .

目錄

第一章：執行摘要

  • 市場簡介
  • 2019-2029年全球和細分市場的估計和預測
    • 2019-2029年，按地區分類的微生物組治療劑市場
    • 2019-2029年，按類型分類的微生物組治療劑市場
    • 2019-2029年，按應用分類的微生物組治療劑市場
  • 主要趨勢
  • 估算方法
  • 研究假設

第二章：全球微生物組治療劑市場的定義和範圍

  • 本研究的目的
  • 市場定義和範圍
    • 研究的範圍
    • 行業演變
  • 研究涵蓋的年份
  • 貨幣兌換率

第三章：全球微生物組治療學市場動態

  • 微生物組治療劑市場影響分析（2019-2029年）
    • 市場驅動力
      • 越來越多的微生物組治療劑的戰略合作進行研發
      • 目標疾病的發病率增加。
    • 市場挑戰
      • 微生物組治療劑的高成本
    • 市場機會
      • 配方的進步

第四章：全球微生物組治療劑市場行業分析

  • 波特五力模型
    • 供應商的議價能力
    • 買方的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭性的競爭
  • 波特五力模型的未來方法（2019-2029年）
  • PEST分析
    • 政治因素
    • 經濟
    • 社會
    • 技術
  • 投資採用模式
  • 分析師建議和結論
  • 最佳投資機會
  • 最佳策略

第五章：風險評估：COVID-19的影響

  • 評估COVID-19對行業的整體影響
  • COVID-19前和COVID-19後的市場情況

第六章：全球微生物組治療劑市場，按類型分類

  • 市場簡介
  • 按類型分類的全球微生物組治療劑市場，性能-潛力分析
  • 2019-2029年全球微生物組治療劑市場按類型的估計和預測
  • 微生物組治療劑市場，細項分析
    • FMT
    • 微生物組藥物

第7章：全球微生物組治療劑市場，按應用分類

  • 市場簡介
  • 全球微生物組治療劑市場，按應用，性能- 潛力分析
  • 2019-2029年全球微生物組治療劑市場按應用估計和預測的情況
  • 微生物組治療劑市場，細項分析
    • 艱難梭菌
    • 克羅恩病
    • 炎症性腸病
    • 糖尿病
    • 其他疾病

第八章：全球微生物組治療劑市場，區域分析

  • 微生物組治療劑市場，區域市場簡介
  • 北美洲
    • 美國
      • 類型細分估計和預測，2019-2029年
      • 應用分類估計和預測，2019-2029年
    • 加拿大
  • 歐洲微生物組治療劑市場概況
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太地區微生物組治療藥物市場概況
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 亞太其他地區
  • 拉丁美洲微生物組治療劑市場概況
    • 巴西
    • 墨西哥
  • 世界其他地區

第九章：競爭情報

  • 頂級市場戰略
  • 公司簡介
    • OpenBiome
      • 關鍵資訊
      • 概況
      • 財務（取決於數據的可用性）
      • 產品摘要
      • 近期發展情況
    • Seres Therapeutics Inc.
    • 4D Pharma plc.
    • Locus Biosciences, Inc.
    • Enterome SA
    • Finch Therapeutics Group, Inc.
    • Intralytix, Inc.
    • Microbiotica
    • Second Genome
    • Rebiotix Inc.

第十章：研究過程

  • 研究過程
    • 資料探勘
    • 數據分析
    • 市場評估
    • 驗證
    • 出版
  • 研究屬性
  • 研究假設

Global Microbiome Therapeutics Market is valued approximately at USD 92.15 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 35.32% over the forecast period 2022-2029. Microbiome treatments aim to engineer the gut microbiome by applying native or synthetic bacteria, antibiotics, bacteriophages, and bacteriocins in additive, subtractive, or modulatory therapy. The market is expanding as a result of factors including the rise in strategic partnerships for R&D, product development, and portfolio expansion in the field of microbiome therapies. Most of the therapeutic drugs in development are still in their early stages, typically between Phase I and Phase II. Out of the 23, more than 13 medicines are being studied for GI indications, with the majority focusing on ulcerative colitis. For instance, Seres Therapeutics, Inc. disclosed SER-109 trial results from its Phase 3 ECOSPOR III study in 2021. It is planned to introduce the pipeline medicine in the first half of 2023 as an oral treatment for recurrent C. difficile infection. SER-109 is connected to a decrease in antimicrobial resistance genes as opposed to placebo. Also, a 4-year partnership for the development and discovery of microbial medicines was established in January 2022 between Hudson Institute and BiomeBank.

The demand for microbiome therapies is also rising as target diseases are becoming more prevalent. The development of microbiome research is anticipated to hunt for more effective cures for infections and other ailments, improving the results of medical therapy. Companies are bringing down the cost of their goods, increasing access to cutting-edge healthcare for a greater percentage of the population, and some countries' governing authorities are changing their strategies to support the adoption of microbiome-based treatments. As a result, this offers market vendors lucrative growth opportunities to increase their market share. The high cost of microbiome treatments and strict regulatory rules brought on by the product's complexity are the two main issues limiting the market's expansion.

The key regions considered for the Global Microbiome Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. With the biggest market share in 2021, North America dominated the industry. The region's dominance is mostly due to its well-established research capabilities for the creation of innovative treatments and its expanding target population. Also, the ubiquity of initiatives like the Canadian Microbiome Initiative (CMI) in Canada makes it easier to work with partners and stakeholders. This makes it possible to concentrate research efforts on the creation of microbial medicines. For instance, the Biocodex Microbiota Foundation published a call for submissions in July 2021 for microbiome research funding totaling more than USD 26,000 in Canada. These incentives are anticipated to stimulate new market innovations. Asia Pacific is predicted to grow significantly during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for biosimilar development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market players included in this report are:

  • OpenBiome
  • Seres Therapeutics Inc.
  • 4D Pharma plc.
  • Locus Biosciences, Inc.
  • Enterome SA
  • Finch Therapeutics Group, Inc.
  • Intralytix, Inc.
  • Microbiotica
  • Second Genome
  • Rebiotix Inc.

Recent Developments in the Market:

  • In December 2021, Kaleido Biosciences and Janssen have joined forces to explore the possibility of microbiome metabolic medicines for the treatment of immunological, atopic, and metabolic diseases that first appear in childhood.
  • in July 2021, The Biocodex Microbiota Foundation published a request for submissions for microbiome research funding totalling more than USD 26,000 in Canada. These incentives are anticipated to stimulate new market innovations.

Global Microbiome Therapeutics Market Report Scope:

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Type, Application, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Type:

  • FMT
  • Microbiome Drugs

By Application:

  • C. difficile
  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Diabetes
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Microbiome Therapeutics Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Microbiome Therapeutics Market, by Type, 2019-2029 (USD Billion)
    • 1.2.3. Microbiome Therapeutics Market, by Application, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Microbiome Therapeutics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Microbiome Therapeutics Market Dynamics

  • 3.1. Microbiome Therapeutics Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing number of strategic collaborations for microbiome therapeutics for R&D
      • 3.1.1.2. Increase in the prevalence of target diseases.
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Microbiome Therapeutics
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Advancements in Formulation

Chapter 4. Global Microbiome Therapeutics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Investment Adoption Model
  • 4.5. Analyst Recommendation & Conclusion
  • 4.6. Top investment opportunity
  • 4.7. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Microbiome Therapeutics Market, by Type

  • 6.1. Market Snapshot
  • 6.2. Global Microbiome Therapeutics Market by Type, Performance - Potential Analysis
  • 6.3. Global Microbiome Therapeutics Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
  • 6.4. Microbiome Therapeutics Market, Sub Segment Analysis
    • 6.4.1. FMT
    • 6.4.2. Microbiome Drugs

Chapter 7. Global Microbiome Therapeutics Market, by Application

  • 7.1. Market Snapshot
  • 7.2. Global Microbiome Therapeutics Market by Application, Performance - Potential Analysis
  • 7.3. Global Microbiome Therapeutics Market Estimates & Forecasts by Application 2019-2029 (USD Billion)
  • 7.4. Microbiome Therapeutics Market, Sub Segment Analysis
    • 7.4.1. C. difficile
    • 7.4.2. Crohn's Disease
    • 7.4.3. Inflammatory Bowel Disease
    • 7.4.4. Diabetes
    • 7.4.5. Others

Chapter 8. Global Microbiome Therapeutics Market, Regional Analysis

  • 8.1. Microbiome Therapeutics Market, Regional Market Snapshot
  • 8.2. North America Microbiome Therapeutics Market
    • 8.2.1. U.S. Microbiome Therapeutics Market
      • 8.2.1.1. Type breakdown estimates & forecasts, 2019-2029
      • 8.2.1.2. Application breakdown estimates & forecasts, 2019-2029
    • 8.2.2. Canada Microbiome Therapeutics Market
  • 8.3. Europe Microbiome Therapeutics Market Snapshot
    • 8.3.1. U.K. Microbiome Therapeutics Market
    • 8.3.2. Germany Microbiome Therapeutics Market
    • 8.3.3. France Microbiome Therapeutics Market
    • 8.3.4. Spain Microbiome Therapeutics Market
    • 8.3.5. Italy Microbiome Therapeutics Market
    • 8.3.6. Rest of Europe Microbiome Therapeutics Market
  • 8.4. Asia-Pacific Microbiome Therapeutics Market Snapshot
    • 8.4.1. China Microbiome Therapeutics Market
    • 8.4.2. India Microbiome Therapeutics Market
    • 8.4.3. Japan Microbiome Therapeutics Market
    • 8.4.4. Australia Microbiome Therapeutics Market
    • 8.4.5. South Korea Microbiome Therapeutics Market
    • 8.4.6. Rest of Asia Pacific Microbiome Therapeutics Market
  • 8.5. Latin America Microbiome Therapeutics Market Snapshot
    • 8.5.1. Brazil Microbiome Therapeutics Market
    • 8.5.2. Mexico Microbiome Therapeutics Market
  • 8.6. Rest of The World Microbiome Therapeutics Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. OpenBiome
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Seres Therapeutics Inc.
    • 9.2.3. 4D Pharma plc.
    • 9.2.4. Locus Biosciences, Inc.
    • 9.2.5. Enterome SA
    • 9.2.6. Finch Therapeutics Group, Inc.
    • 9.2.7. Intralytix, Inc.
    • 9.2.8. Microbiotica
    • 9.2.9. Second Genome
    • 9.2.10. Rebiotix Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Microbiome Therapeutics Market, report scope
  • TABLE 2. Global Microbiome Therapeutics Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Microbiome Therapeutics Market estimates & forecasts by Type 2019-2029 (USD Billion)
  • TABLE 4. Global Microbiome Therapeutics Market estimates & forecasts by Application 2019-2029 (USD Billion)
  • TABLE 5. Global Microbiome Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Microbiome Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Microbiome Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Microbiome Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Microbiome Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Microbiome Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Microbiome Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Microbiome Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Microbiome Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Microbiome Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. U.S. Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. Canada Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 19. Canada Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. UK Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 22. UK Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. Germany Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 25. Germany Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. France Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 28. France Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. Italy Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 31. Italy Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Spain Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 34. Spain Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. RoE Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 37. RoE Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. China Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 40. China Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. India Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 43. India Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. Japan Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 46. Japan Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. South Korea Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 49. South Korea Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. Australia Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 52. Australia Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. Brazil Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 58. Brazil Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Mexico Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 61. Mexico Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. RoLA Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 64. RoLA Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. Row Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 67. Row Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Microbiome Therapeutics Market
  • TABLE 70. List of primary sources, used in the study of global Microbiome Therapeutics Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Microbiome Therapeutics Market, research methodology
  • FIG 2. Global Microbiome Therapeutics Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Microbiome Therapeutics Market, key trends 2021
  • FIG 5. Global Microbiome Therapeutics Market, growth prospects 2022-2029
  • FIG 6. Global Microbiome Therapeutics Market, porters 5 force model
  • FIG 7. Global Microbiome Therapeutics Market, pest analysis
  • FIG 8. Global Microbiome Therapeutics Market, value chain analysis
  • FIG 9. Global Microbiome Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Microbiome Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Microbiome Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Microbiome Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Microbiome Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Microbiome Therapeutics Market, regional snapshot 2019 & 2029
  • FIG 15. North America Microbiome Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Microbiome Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Microbiome Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Microbiome Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Microbiome Therapeutics Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable